Comparison between Paramesu Biotech IPO and Viney IPO.
Paramesu Biotech IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Viney IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
| Paramesu Biotech IPO | Viney IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | Mainboard | Mainboard |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | BSE, NSE | BSE, NSE |
| Lead Managers | Pantomath Capital Advisors Pvt.Ltd. | Axis Capital Ltd. ICICI Securities Ltd. |
| Registrar | Bigshare Services Pvt.Ltd. | MUFG Intime India Pvt.Ltd. |
| Market Maker | ||
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | ||
| IPO Allotment URL |
The total issue size of Paramesu Biotech IPO is up to ₹600.00 Cr whereas the issue size of the Viney IPO is up to ₹0.00 Cr. The final issue price of Paramesu Biotech IPO is and of Viney IPO is .
| Paramesu Biotech IPO | Viney IPO | |
|---|---|---|
| Face Value | ₹5 per share | ₹10 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ||
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | ||
| Fresh Issue Size | 0 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹520.00 Cr | up to ₹150.00 Cr |
| OFS Issue Size | 0 shares | 2,22,13,852 shares |
| OFS Issue Size (Amount) | up to ₹80.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 0 shares | 0 shares |
| Issue Size Total (Amount) | up to ₹600.00 Cr | up to ₹0.00 Cr |
Paramesu Biotech IPO opens on , while Viney IPO opens on . The closing date of Paramesu Biotech IPO and Viney IPO is , and , respectively.
Paramesu Biotech IPO P/E ratio is , as compared to Viney IPO P/E ratio of .
| Paramesu Biotech IPO | Viney IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)
| Company Financials (Restated Consolidated)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 92.19 | 100 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 23.30% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 18.13% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 23.30% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Paramesu Biotech IPO Retail Individual Investors (RII) are offered 0 shares while in Viney IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Paramesu Biotech IPO and in Viney IPO.
| Paramesu Biotech IPO | Viney IPO | |
|---|---|---|
| Anchor Investor Reservation | ||
| Market Maker Reservation | 0 shares | |
| QIB | 0 shares | |
| NII | 0 shares | |
| RII | 0 shares | |
| Employee | 0 shares | |
| Others | ||
| Total | 0 shares |
Paramesu Biotech IPO subscribed in total, whereas Viney IPO subscribed .
| Paramesu Biotech IPO | Viney IPO | |
|---|---|---|
| QIB (times) | ||
| NII (times) | ||
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | ||
| Employee (times) | ||
| Other (times) | ||
| Total (times) |
